|
|
|
Agenda
Day One – Sept 10
| 7:30am |
Registration
|
| 8:30am |
Introduction and Opening Remarks
Session Chair: Umesh Patel, Director - Ion Channel Discovery Group, Millipore
|
|
8:35am |
Keynote Address - Pharmacological Modulation of Ca2+ Sensitivity of Small Conductance Ca2+-Activated K+ Channels: A Challenge in Drug Discovery
Palle Christophersen, Director - Electrophysiology, Neurosearch
|
| 9:25am
|
Technology: Fluorescence, Cells and New Targets
Session Chair: Umesh Patel, Director - Ion Channel Discovery Group, Millipore
|
|
9:55am |
Electrophysiological Assays to Identify Epithelial Sodium Channel (ENaC) Activators
Bryan Moyer, Principal Scientist, Senomyx
|
|
9:55am |
Actual vs. Assumed Compound Concentration in Ion Channel Screening Assays: Issues and Solutions
Arnon Chait, President, Analiza
Measurement of compound solubility, stock concentration, and final dose can all be accomplished with a rapid chemiluminescent nitrogen detection technique, providing an accurate determination of dose response which is critical for ion channel screening.
|
|
10:25am |
Coffee and Networking in Exhibit Hall
|
|
11:10am |
Development of Cellular Tools for High-throughput Screening of Voltage Gated Sodium Channels
Colin Dick, Ion Channel Projects Manager, Scottish Biomedical
|
|
11:40am |
Evaluating Ion Channel Mechanisms in Murine Neuronal Cultures and Human Embroyonic Stem Cell-derived Neurons Using FLIPR and Flex Station
Thomas Murray, Professor and Chair, Creighton University Medical School
|
| 12:10pm |
LOPAC Screen for Neurotransmitter Transporter Uptake Activity Using A Fluorescence-Based, Homogenous Assay
Richard Sportsman, VP - Reagents and Assays, Molecular Devices
Fluorescence cell based assay of neurotransmitter uptake is done with a homogeneous method. Uptake of serotonin, norepiniphrine, and dopamine can be assessed without use of radioactivity. Known pharmacology of inhibitors is faithfully replicated in this system.
|
|
12:40pm |
Lunch and Poster Viewing
|
|
2:10pm |
Technology: Automated Patch Clamp
Session Chair: Jeff Clare, Biological Reagents and Assay Development, GSK
|
| 2:15pm |
Development of Calcium Channel Screening Assays using Automated QPatch-16 Patch Clamp Electrophysiology
Yi Liu, Senior Scientist Analgesics Discovery, Johnson & Johnson Pharmaceutical R&D
|
| 2:45pm |
Chiptips®, A Breakthrough in Automated Patch Clamp
Albrecht Lepple-Wienhues, CEO, flyion GmbH
|
| 3:10pm |
The Use of Planar Array Electrophysiology for the Development of Robust Ion Channel Cell Lines for Drug Discovery
Jeff Clare, Biological Reagents and Assay Development, GSK
|
|
3:45pm |
Coffee and Networking in Exhibit Hall
|
| 4:30pm
|
Ion Channel Focused Library: Rationale and Screening of HCN Ion Channel Targets
Dmitry Vasilyev, Senior Research Scientist II, Wyeth
|
|
5:00pm |
Utilizing Automated Electrophysiology to Develop Ligand-Gated Ion Channel Profiling Assays for Drug Discovery
Jonathan Mann, Research Scientist, Millipore
|
|
5:30pm |
Drinks Reception
(Sponsorship opportunity still available, please contact Ian.Slade@selectbiosciences.com)
|
Day Two - September 11
|
9:00am |
Immunity
Session Chair: David Sattelle, Professor, University of Oxford
|
|
9:05am |
Validation of the CRAC Channel as a Potential Target for T Cell-mediated Immune Diseases
Martin Mense, Scientist II, Synta Pharmaceuticals
|
| 9:35am
|
PAP-1, A Small Molecule Kv1.3 Blocker, for the Treatement of Effector Memory T-cell Mediated Autoimmune Diseases
Heike Wulff, Assitant Professor, University of California - Davis
Our results demonstrate that the small molecule Kv1.3 blocker PAP-1 constitutes a promising novel immunosuppressant that could be developed into a topical drug for psoriasis and potentially into an oral drug for other autoimmune diseases.
|
| 10:05am |
Coffee and Networking in Exhibit Hall
|
|
10:50am |
Pain
Session Chair: David Sattelle, Professor, University of Oxford
|
|
10:55am |
Keynote Address - Nicotinic Acetylcholine Receptors: Roles in Disease and as Drug/Chemical Targets
David Sattelle, Professor, University of Oxford
Nicotinic acetylcholine receptors mediate fast cholinergic synaptic transmission. Structural studies, genomics, genetics and physiology are enhancing our understanding of the functions of nAChRs. Their roles in human sporadic, genetic and autoimmune diseases of the nervous system and neuromuscular junctions makes these ionotropic receptors and their associated proteins important drug targets.
|
|
11:40am |
The Voltage-gated Sodium Channel Nav1.7 in Analgesia: Target Validity and Screening Strategies
Johannes Krupp, Section Head – Lead Discovery Biology, AstraZeneca
|
|
12:10pm |
Lunch and Poster Viewing
|
|
1:40pm |
Subtype-selective Sodium Channel Blockers for the Treatment of Pain
Douglas Krafte, VP Biology, Icagen
Sodium channel blockers are effective therapeutics, but typically block many sodium channel subtypes. We have demonstrated that subtype-selective blockers can be identified which may lead to a next generation of compound with efficacy and an improved therapeutic index.
|
|
2:10pm |
The Heart
Session Chair: Michael Xie, Senior Director, Head of Biology, Epix Pharmaceuticals
|
| 2:15pm |
Cardiac Safety Assay Tools
Stephen Hess, Research Fellow, Invitrogen
|
| 2:45pm |
Validation of a L-type Ca Channel Assay and a Rate-dependant Cardiac Na Channel Assay for Lead Optimization Studies on the PatchXpress
John Imredy, Research Fellow, Merck Research Laboratories
|
|
3:15pm |
Coffee and Networking
|
|
4:00pm |
A Comprehensive Cardio Safety Strategy - With the Impact by Emerging Technologies
Qiang Lu, Head - Ion Channel and Cellular Toxicology, Novartis
|
|
4:30pm |
Opening the Gate to Novel Ion Channel Modulators and Innovative Anti-arrhythmics
Petra Blom, Section Leader - Medicinal Chemistry, Devgen
Devgen’s innovative approach to treat AF by blocking the Ito current will be discussed. The compelling data obtained in several animal models will demonstrate the high potential of these unique Kv4.3 inhibitors for a safe and effective treatment of AF.
|
| 5:00pm |
Close of Conference |
|